Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 5/20 | 0.47 |
| ▸ | PRKDC | P78527 | 6/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30562966 | 0.93 | IRAK4 (0.48) | ENPP1LRRK2PDE3BPDE3APDE10A | |
| SCHEMBL21664243 | 0.93 | IRAK4 (0.48) | ENPP1LRRK2PDE3BPDE3APDE10A | |
| SCHEMBL21664334 | 0.86 | ENPP1 (0.49) | ENPP1PRKDC | |
| SCHEMBL21664310 | 0.85 | CYP1A2 (0.54) | ENPP1PRKDCPDE10APDGFRBBTK | |
| SCHEMBL21664254 | 0.85 | ENPP1 (0.48) | ENPP1PRKDC | |
| SCHEMBL24064739 | 0.85 | ENPP1 (0.48) | ENPP1PRKDCPDE3A | |
| SCHEMBL21664309 | 0.84 | LMNA (0.50) | ENPP1PRKDCPDE3AHRH4 | |
| SCHEMBL26557870 | 0.84 | PRKDC (0.54) | PRKDCLRRK2PDE3BPDE3APDE10A | |
| SCHEMBL21664293 | 0.83 | ENPP1 (0.47) | ENPP1PRKDCLRRK2PDE3APDE10A | |
| SCHEMBL21664259 | 0.83 | ENPP1 (0.47) | ENPP1PRKDCLRRK2PDE3APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11752153-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2023-09-12 | — | — | US | disclosed |
| US-11752153-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2023-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11752153-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | TXN, TXNL1, TXN2 | ENPP1 2704/4885PRKDC 4313/4885LRRK2 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.